rational exploration of the underground

Serotonin (5-hydroxytryptamine, ST, 5HT) is a hydroxylated tryptamine, a class of compounds which rose to widespread fame in the psychedelic drug community with the publication of Alexander Shulgin’s work “Tryptamines I Have Known and Loved“. Most of the body’s serotonin (80%+) is produced and contained in the digestive tract, where it regulates intestinal movements. The remainder is synthesized in Raphe cells deep along the midline core of the brainstem, where it is involved in activities such as mood, appetite, sleep, muscle contraction, memory, and learning. Raphe cells start to fire slowly, and their firing also tails off slowly. This reflects a system designed to modulate slower state-dependent activities, rather than a quick response to external stimuli.

Serotonin is present in all bilaterally symmetric animals, and acts to modulate digestive movements and is involved in the perception of resource availability. For very simple animals resources could only mean food, but in more advanced animals such as primates this also includes social status (or lack of it). Serotonin can modulate an animal’s rate of growth, desire to reproduce, and overall mood in relation to the perceived abundance or scarcity of these resources. In roundworms serotonin is released as a signal in response to positive events such as finding a new grazing ground or meeting a suitable mate. Lobsters injected with serotonin begin to display dominant social behavior, regardless of previous social status.

There are at least three major families of serotonin receptors. Many psychedelic drugs, such as psilocybin, act as partial serotonin agonists primarily active at the 5HT2 receptor. But there is some action at additional receptors, including not surprisingly the 5HT3 receptor involved in feelings of nausea. 5HT3 antagonists such as ondansetron are used during chemotherapy and are considered the gold standard in anti-nausea treatment.

In primates, many serotonin terminals end in the fourth layer of the visual cortex, where they can influence visual perception. Additionally, the temporal lobe is rich in serotonin nerve cell endings, meaning serotonin action has a significant influence on the stream of visual interpretations and association arising from external stimuli. Serotonin tends to act generally as an inhibitor in the cortex, where it reduces the excitatory responses evoked by other sensory stimuli. It also tends to preserve the general noise level of firing in the background, reducing the signal to noise ratio in contrast to the action of norepinephrine.

In humans, low serotonin levels are correlated with certain states of depression. This is reinforced by the fact that consumption of the serotonin precursor 5-hydroxytryptophan (5HTP) causes alleviation of depressive symptoms in some patients. The brain normally has a dense concentration of postsynaptic 5HT2 receptors in the prefrontal cortex, the location in the brain thought to play an “executive” role in coordinating sensory response. Patients who have had a major depressive incident tend to have even higher numbers of these receptors, which is thought to be a result of the brain compensating for lower serotonin levels. In the brain stems of depressed subjects, autopsies have also shown reduced serotonin levels.

Increases in serotonin levels tend to have the opposite effect, increasing outward social behaviours. In monkeys, serotonin agonist drugs increase the approaching, grooming, resting, and eating activities typical of the dominant males. They also reduce inward social solitary, vigilant, and avoidance behaviors. This is reflected in humans under the influence of MDMA, an amphetamine derivative which simultaneously releases large amounts of serotonin while blocking its reuptake. Subjects become much more social and talkative, empathy towards others is increased, and anxiety and paranoia disappear. This has made MDMA and related compounds ideal for psychiatric therapy, particularly for couples and those who have experienced intensely traumatic events.

But the “serotonin as happiness” message sold by drug companies pushing antidepressants is not a complete story. A depressed person may have decreased serotonin levels in response to environmental or other factors, and an antidepressant will certainly raise them. But if these stress factors do not change along with the serotonin levels (through changes in behavior or the environment itself), it is unlikely to create lasting positive change. Serotonin appears to act to regulate the extent or intensity of moods, with less influence on the direct attitude of the mood itself. Similar to the use of MDMA in therapy, these drugs should be regarded as a catalyst to move in the correct direction, and not a magic bullet.

Norepinephrine (NE) is a neurotransmitter, involved in behaviours including alertness, anxiety, and attention. Most norepinephrine cells cluster in a pair of nuclei called the locus coeruleus, Latin for a “blue spot” in the brain stem. Each locus coeruleus is a long tube shaped cluster of norepinephrine neurons, both consisting of only 45,000 to 60,000 nerve cells in total. A second group of nerve cells arises deeper down in the medulla, and delivers norepinephrine mostly to the hypothalamus.

Primate brains have a dense network supplying norepinephrine to the posterior parietal lobe (which integrates sensory information), to part of the thalamus, and to the outer layers of the optic lobes in the midbrain. Relatively little norepinephrine is supplied to the temporal cortex, involved in speech, high-level visual processing (ie facial recognition), and memory. This outlines a distinctive feature of norepinephrine, that it is generally involved in direct sensory input rather than sensory processing. But the hypothalamus (which regulates hunger, thirst, fatigue, and sleep cycles) has the highest concentration of norepinephrine at 1150 nanograms per gram, indicating the vital role this neurotransmitter plays in deep primal instincts.

NE cells in the locus coeruleus fire especially in response to stressful, painful, noxious stimuli. In rats, they fire faster for up to thirty seconds if the toe is compressed in a painful manner. A strong but generic stimuli for cats (say a loud noise) will prompt a brief discharge of norepinephrine, but this response dwindles as the stimuli is repeated and the cat becomes conditioned.

In higher primates like monkeys, pain and stress also cause norepinephrine cells to fire faster. But what really gets monkey norepinephrine production going is fruit juice, their favorite treat. Norepinephrine cells fire at their highest rates when drinking fruit juice, seven to fifteen times per second. The norepinephrine cells of primate brains appear to be slightly different than that of lower animals, as they are especially activated by noxious stimuli and also certain specific attractive stimuli. Norepinephrine cells fire much slower if primates are given opiate based painkillers however, and during dream states (REM) of sleep.

So what exactly happens when norepinephrine cells fire more frequently? They appear to have rather few direct effects, but act primarily as a modulator. For instance, norepinephrine alone does little to change the slow background firing of cells in the hippocampus proper (involved in memory and spatial navigation) – but if these cells have been excited by addition of glutamate, norepinephrine makes them fire even faster. Norepinephrine also makes hippocampal cells fire faster if they have been excited by natural outside visual and auditory stimuli. It also reduces spontaneous background activity, increasing the signal to noise ratio of sensation from outside. This increased signal to noise ratio has become very valuable in treating symptoms of conditions such as ADHD. Norepinephrine and dopamine both play a large role in attention and focus. Various amphetamines and other compounds like methylphenidate (Ritalin) prescribed for ADHD cause higher levels of norepinephrine and dopamine.

Other compounds can act as agonists at norepinephrine receptors. Clonidine is used to relieve the suffering of addicts withdrawing from opiates. It activates certain autoreceptors which slow the norepinephrine cells’ firing rate, reducing symptoms such as anxiety, restlessness, and aching in muscles and joints. This clinical success emphasizes the theories linking excessive norepinephrine activity within the locus coeruleus with states of anxiety and tension. For instance, investigation into patients suffering panic attacks suggests that they may lack the normal mechanisms that would hold their norepinephrine systems in check.

A great paper just came out in the Canadian Medical Association Journal, dealing with the ability of cannabis to combat neuropathic pain. Neuropathic pain is thought to be caused by damage to the nervous system, and often does not respond to conventional painkillers. It is estimated that 1-2% of the adult population is affected, and patients with this chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood.

Suffice to say that most of the time this isn’t suggested by doctors and dispensed by prescription. So does it actually work? 21 adults with post-traumatic or postsurgical neuropathic pain completed the study, and were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% THC). They assigned the various strengths of cannabis as part of a “crossover trial”, where each subject would receive one of the concentrations randomly for a two week period. After four two-week periods and random “crossovers” to other potencies, everyone had tried every potency.

Participants inhaled a single 25-mg dose of cannabis through a pipe three times daily for the first five days in each two-week period, followed by a nine-day washout period before the next trial. Daily average pain intensity was measured using an 11-point scale, and effects on mood, sleep, quality of life, and adverse events were recorded.

And the results? Turns out that you need decent pot for pain relief, but it doesn’t have to be an insanely potent strain. Lower potency cannabis did not significantly reduce pain, but the 9.4% THC cannabis reduced pain, improved ability to fall asleep, and improved quality of sleep. The beautiful outcome is that cannabis containing 10% THC is widely available and only 75mg a day (slightly over two grams a month) is needed to cause statistically significant improvements for those suffering chronic pain.

Mark A. Ware, Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, Ann Gamsa, Gary J. Bennett, Jean-Paul Collet, Smoked cannabis for chronic neuropathic pain: a randomized controlled trial, Canadian Medical Association Journal, Volume 182, Number 14, 2010, Pages 694-701.

The three potent neurotransmitters dopamine, norepinephrine, and serotonin were known to science prior to the 1960s, but the precise structure and extent of their nerve cells was unclear. Annica Dahlström and Kjell Fuxe used the novel technique of histoflourescence to map the pathways that released them into the brain in a landmark paper in 1964, “Evidence for the existence of monoamine neurons in the central nervous system“. The field exploded, and strange facts emerged. They are greatly outnumbered, as our brain only holds a million or so of them. But they exert a huge influence over the remaining billions of other nerve cells, fanning out into up to 500,000 nerve endings connecting to hundreds of other distant cells.

Acetylcholine (ACh) was the first neurotransmitter to be discovered. Identified in the year 1914 by Henry Hallett Dale for its actions on heart tissue, it was confirmed as a neurotransmitter by Otto Loewi. Both received the 1936 Nobel Prize in Medicine for their work. The nerve cells that release ACh are widespread and influential, involved in alertness, arousal, memory, and the fast brain waves which occur during waking and REM sleep.

In the peripheral nervous system, acetylcholine activates muscles, and is a major neurotransmitter in the autonomic nervous system. In the central nervous system, acetylcholine and the associated neurons form a neurotransmitter system, the cholinergic system, which is associated with anti-excitatory actions. ACh is also involved with synaptic plasticity, specifically in learning and short-term memory.

There are two main types of ACh receptors.

Nicotinic Acetylcholine Receptors

The first type of ACh receptor is called nicotinic, from the familiar compound nicotine of the tobacco plant. Nicotine was found to act as an ACh agonist, or compound that mimicked the action of ACh at these receptors. If you deliver nicotine to thalamic nerve cells, they fire instantly. Where are these nicotinic receptors prone to quick discharge? They reside in the medulla, hypothalamus, thalamus, in the cerebellum, and to a lesser degree in the cerebral cortex.

The stimulating effect of nicotine peaks within one minute after intravenous injection, wearing off a few minutes later. Any former smoker knows the pangs of nicotine withdrawal as the stimulating effect of nicotine is removed. Strangely enough, human subjects cannot distinguish between the euphoriant effect of nicotine and that of morphine or amphetamine. Does this imply that ACh agonism causes secondary release of other brain opioids or amines? The hypothesis is not well studied and is unresolved.

The primary effect is well established however. When nicotine activates presynaptic receptors, it causes a major enhancement of fast excitatory transmission. The immediate rush from smoking a cigarette appears to reflect the way that these nicotinic receptors are opening up the “nozzle” on other incoming terminals, allowing them to release much more of their fast acting ACh or glutamate transmitters into the synapse.

So what about antagonists, compounds that bind to the receptor but block action by not activating it? These include compounds used to cause peripheral muscle paralysis during surgery (as acetylcholine activates muscles, remember) and the antidepressant/smoking cessation aid bupropion. Bupropion binds to receptors and has a long half-life – so it sticks around, preventing any nicotine from binding to the receptors which would create a pleasurable response, making smoking cigarettes useless.

Muscarinic Acetylcholine Receptors

In the nineteenth century, the compound muscarine was isolated from the psychoactive mushroom Amanita muscaria. The mushroom itself in higher doses causes hallucinations, and was used intoxicant and entheogen by the peoples of Siberia. Muscarine was subsequently found to act as an ACh agonist on this class of receptors. They are located in diverse regions of the brain, and in contrast to the nicotinic receptors, begin to excite the next cell relatively slowly. For instance, a thalamic cell won’t increase its firing rate until 1.2 seconds after their incoming ACh receptors have been stimulated deep in the brain stem. But this slow start then develops momentum, as the thalamic cells continue to discharge for as long as 21 seconds. During this time, other thalamic cells become increasingly excited and develop fast, 35-45 Hz gamma rhythms. These rhythms may then be transmitted up to the cortex, as brain EEG scans begin to illustrate similar frequencies.

An opposing drug to muscarine is atropine, a muscarinic ACh antagonist. Named after Atropos, one of the three Fates in Greek mythology who chose how you were to die, atropine and related antagonists are found in plants such as belladonna and datura. Ingested in sufficient quantity, they cause strong and unpleasant deliriant effects with a distinct risk of death from toxicity or risky atypical behaviour. Even a modest blocking dose of atropine (1.25mg) demonstrates the risk of muscarinic antagonism. Subjects do not think as clearly, and struggle to maintain focused attention on even the simplest of tasks.